Shares of UCB SA (OTCMKTS:UCBJF – Get Free Report) saw unusually-strong trading volume on Wednesday . Approximately 7,591 shares traded hands during mid-day trading, an increase of 986% from the previous session’s volume of 699 shares.The stock last traded at $295.59 and had previously closed at $287.84.
Wall Street Analyst Weigh In
Separately, Piper Sandler reissued a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, UCB has an average rating of “Moderate Buy”.
UCB Stock Performance
UCB Company Profile
UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.
Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.
Further Reading
- Five stocks we like better than UCB
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
